They include fatigue, depression and cytopenia.7 This treatment proved to be a crucial therapeutic option for the patient in a setting where targeted therapies are unavailable and the BRAF mutation status remained unknow to date. This evidence concerns the gene BRAF and depressive symptom measurement.